Kathleen Corona, APRN
Family · Salina, KSNPI 1316293566
Payments from drug & device makers
Across 165 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$580
- Lilly USA, LLC$489
- Pfizer$283
- Amgen$252
- Novo Nordisk$207
- Merck$114
- plus $559 from 19 others
What the payments were for
- Food & beverage$2,483100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $580 |
| Lilly USA, LLC | 30 | $489 |
| Pfizer | 21 | $283 |
| Amgen | 17 | $252 |
| Novo Nordisk | 15 | $207 |
| Merck | 10 | $114 |
| AstraZeneca | 7 | $104 |
| GSK | 4 | $66 |
| Bayer | 4 | $55 |
| Amarin Pharma, Inc. | 2 | $50 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Medtronic | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Abbott | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$2,483 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $79,732 |
| MounjaroTirzepatide | 42 | $43,584 |
| TrulicityDulaglutide | 37 | $35,366 |
| JardianceEmpagliflozin | 22 | $17,067 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,817 |
| JanuviaSitagliptin Phosphate | 18 | $14,722 |
| FarxigaDapagliflozin Propanediol | 13 | $11,187 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $10,805 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,832 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,633 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 39 | $8,598 |
| MyrbetriqMirabegron | 15 | $7,767 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 263 | $7,598 |
| LinzessLinaclotide | 12 | $6,395 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $5,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $283 | $79,732101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $489 | $78,95179 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $14 | $26,70041 claims |
| GSKTrelegy Ellipta, Shingrix | $66 | $23,41557 claims |
| MerckJanuvia | $114 | $14,72218 claims |
| AstraZenecaFarxiga | $104 | $11,18713 claims |
| AbbVieLinzess, Synthroid | $580 | $8,71661 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $7,76715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,579 family providers in Kansas.
Other family in Salina
- Jettie LegerSalina$6K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.